TH1/TH2 cytokine levels as an indicator for disease progression in human immunodeficiency virus type 1 infection and response to antiretroviral therapy. 2010

Chukwunomso E Osakwe, and Coralia Bleotu, and Mariana Carmen Chifiriuc, and Camelia Grancea, and Dan Oţelea, and Simona Paraschiv, and Sorin Petrea, and Magda Dinu, and Cristian Băicuş, and Adrian Streinu-Cercel, and Veronica Lazăr
University of Bucharest, Faculty of Biology, Microbiology and Immunology Department, 1-3 Aleea Portocalelor, 70709, Bucharest, Romania. ekeneosakwe@yahoo.com

A recent theory stipulates that during the course of HIV infection, there is a shift in immune response from T-helper 1 to T-helper 2 responses, characterised by elevated secretions of relevant cytokines. Cytokine profiles of 15 asymptomatic (treatment naïve) and 26 symptomatic (undergoing treatment) HIV-1 patients was determined to investigate the validity of this theory. HIV-1 RNA was quantified using the COBAS TaqMan HIV-1 test, CD4 T-cell counts with the FACSCalibur flow cytometer and IL-1, IL-4, IL-6, IL-10 and IFN-gamma cytokine levels by ELISA method. The asymptomatic group had significantly higher RNA levels (p-value; 0.000006) and lower CD4 T-cell counts than the symptomatic group indicating ongoing disease progression in the absence of antiretroviral treatment and a positive response to HIV treatment by the symptomatic group. IL-1, IL-4 and IFN-gamma were undetectable in most study subjects. IL-10 and IL-6 levels was relatively lower in the asymptomatic group (mean value; 206.352 pg/ml, 10.516 pg/ml) than the symptomatic group (mean value; 417.539, 18.387 pg/ml). Lower levels of proinflammatory cytokines (IL-1, IFN-gamma) in both study groups and elevated levels of anti-inflammatory cytokine IL-10, confirms that there is a shift in immune response as HIV infection progress to AIDS. In addition, the presence of a progressive trend of anti-inflammatory cytokine, IL-10 and proinflammatory cytokine, IL-6 in 12 symptomatic patients tested 3 months after antiretroviral therapy indicates an attempt by antiretrovirals to restore immune function.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D016207 Cytokines Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner. Cytokine
D018417 Th1 Cells A subset of helper-inducer T-lymphocytes which synthesize and secrete INTERLEUKIN-2; INTERFERON-GAMMA; and INTERLEUKIN-12. Due to their ability to kill antigen-presenting cells and their lymphokine-mediated effector activity, Th1 cells are associated with vigorous delayed-type hypersensitivity reactions. T Helper 1 Cells,TH-1 Cells,Type 1 Helper T Cells,Cell, TH-1,Cell, Th1,Cells, TH-1,Cells, Th1,TH 1 Cells,TH-1 Cell,Th1 Cell
D018418 Th2 Cells A subset of helper-inducer T-lymphocytes which synthesize and secrete the INTERLEUKINS IL-4; IL-5; IL-6; and IL-10. These cytokines influence B-cell development and antibody production as well as augmenting humoral responses. T Helper 2 Cell,T Helper2 Cell,TH-2 Cell,Th2 Cell,Type-2 Helper T Cell,T Helper 2 Cells,T Helper2 Cells,TH-2 Cells,Type-2 Helper T Cells,Cell, T Helper2,Cell, TH-2,Cell, Th2,Cells, T Helper2,Cells, TH-2,Cells, Th2,TH 2 Cell,TH 2 Cells,Type 2 Helper T Cell,Type 2 Helper T Cells
D018450 Disease Progression The worsening and general progression of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis. Clinical Course,Clinical Progression,Disease Exacerbation,Exacerbation, Disease,Progression, Clinical,Progression, Disease
D019380 Anti-HIV Agents Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS. AIDS Drug,AIDS Drugs,Anti-AIDS Agents,Anti-AIDS Drug,Anti-HIV Agent,Anti-HIV Drug,Anti-AIDS Drugs,Anti-HIV Drugs,Agent, Anti-HIV,Agents, Anti-AIDS,Agents, Anti-HIV,Anti AIDS Agents,Anti AIDS Drug,Anti AIDS Drugs,Anti HIV Agent,Anti HIV Agents,Anti HIV Drug,Anti HIV Drugs,Drug, AIDS,Drug, Anti-AIDS,Drug, Anti-HIV,Drugs, AIDS,Drugs, Anti-AIDS,Drugs, Anti-HIV

Related Publications

Chukwunomso E Osakwe, and Coralia Bleotu, and Mariana Carmen Chifiriuc, and Camelia Grancea, and Dan Oţelea, and Simona Paraschiv, and Sorin Petrea, and Magda Dinu, and Cristian Băicuş, and Adrian Streinu-Cercel, and Veronica Lazăr
June 1998, Journal of virology,
Chukwunomso E Osakwe, and Coralia Bleotu, and Mariana Carmen Chifiriuc, and Camelia Grancea, and Dan Oţelea, and Simona Paraschiv, and Sorin Petrea, and Magda Dinu, and Cristian Băicuş, and Adrian Streinu-Cercel, and Veronica Lazăr
August 1995, Australian and New Zealand journal of medicine,
Chukwunomso E Osakwe, and Coralia Bleotu, and Mariana Carmen Chifiriuc, and Camelia Grancea, and Dan Oţelea, and Simona Paraschiv, and Sorin Petrea, and Magda Dinu, and Cristian Băicuş, and Adrian Streinu-Cercel, and Veronica Lazăr
January 1999, Journal of virology,
Chukwunomso E Osakwe, and Coralia Bleotu, and Mariana Carmen Chifiriuc, and Camelia Grancea, and Dan Oţelea, and Simona Paraschiv, and Sorin Petrea, and Magda Dinu, and Cristian Băicuş, and Adrian Streinu-Cercel, and Veronica Lazăr
May 2001, The Journal of infectious diseases,
Chukwunomso E Osakwe, and Coralia Bleotu, and Mariana Carmen Chifiriuc, and Camelia Grancea, and Dan Oţelea, and Simona Paraschiv, and Sorin Petrea, and Magda Dinu, and Cristian Băicuş, and Adrian Streinu-Cercel, and Veronica Lazăr
April 1995, Proceedings of the Association of American Physicians,
Chukwunomso E Osakwe, and Coralia Bleotu, and Mariana Carmen Chifiriuc, and Camelia Grancea, and Dan Oţelea, and Simona Paraschiv, and Sorin Petrea, and Magda Dinu, and Cristian Băicuş, and Adrian Streinu-Cercel, and Veronica Lazăr
August 1989, Clinical chemistry,
Chukwunomso E Osakwe, and Coralia Bleotu, and Mariana Carmen Chifiriuc, and Camelia Grancea, and Dan Oţelea, and Simona Paraschiv, and Sorin Petrea, and Magda Dinu, and Cristian Băicuş, and Adrian Streinu-Cercel, and Veronica Lazăr
April 1998, The Journal of infectious diseases,
Chukwunomso E Osakwe, and Coralia Bleotu, and Mariana Carmen Chifiriuc, and Camelia Grancea, and Dan Oţelea, and Simona Paraschiv, and Sorin Petrea, and Magda Dinu, and Cristian Băicuş, and Adrian Streinu-Cercel, and Veronica Lazăr
June 1996, The Journal of infectious diseases,
Chukwunomso E Osakwe, and Coralia Bleotu, and Mariana Carmen Chifiriuc, and Camelia Grancea, and Dan Oţelea, and Simona Paraschiv, and Sorin Petrea, and Magda Dinu, and Cristian Băicuş, and Adrian Streinu-Cercel, and Veronica Lazăr
May 2003, Clinical and diagnostic laboratory immunology,
Chukwunomso E Osakwe, and Coralia Bleotu, and Mariana Carmen Chifiriuc, and Camelia Grancea, and Dan Oţelea, and Simona Paraschiv, and Sorin Petrea, and Magda Dinu, and Cristian Băicuş, and Adrian Streinu-Cercel, and Veronica Lazăr
January 2012, The Pediatric infectious disease journal,
Copied contents to your clipboard!